ArticleOncoimmunology2020

Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule.

Xitlally Popa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.